PubRank

Barbara S Beckman

Author PubWeight™ 42.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 2004 2.41
2 Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2010 1.45
3 MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta 2011 1.39
4 Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 2008 1.35
5 Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 2006 1.31
6 Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010 1.29
7 Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 2009 1.29
8 Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004 1.28
9 Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002 1.27
10 Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011 1.24
11 Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 2008 1.15
12 Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer 2010 1.08
13 NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 2002 1.05
14 Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. J Pharmacol Exp Ther 2009 1.05
15 Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 2004 1.04
16 Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol 2010 1.01
17 Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol 2011 0.99
18 Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 2009 0.98
19 Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol 2007 0.98
20 Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Mol Carcinog 2012 0.94
21 Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis 2003 0.94
22 AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res 2006 0.93
23 A review of ceramide analogs as potential anticancer agents. Future Med Chem 2013 0.92
24 Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci Rep 2012 0.90
25 Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 2009 0.90
26 Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest 2012 0.89
27 Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol 2010 0.89
28 Integrin-linked kinase: a hypoxia-induced anti-apoptotic factor exploited by cancer cells. Int J Oncol 2007 0.88
29 A novel hypoxia-response element in the lactate dehydrogenase-B gene of the killifish Fundulus heteroclitus. Comp Biochem Physiol A Mol Integr Physiol 2009 0.86
30 Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway. Toxicol Lett 2005 0.85
31 MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS One 2013 0.84
32 Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med (Maywood) 2012 0.84
33 Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncol Rep 2012 0.83
34 Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Res 2013 0.83
35 PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. Int J Oncol 2005 0.82
36 Glyceollin I enantiomers distinctly regulate ER-mediated gene expression. Steroids 2010 0.82
37 Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer. Bioorg Med Chem Lett 2012 0.81
38 Sphingosine kinase: a promising cancer therapeutic target. Cancer Biol Ther 2011 0.80
39 Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. J Endocrinol 2012 0.79
40 Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. Bioorg Med Chem 2010 0.79
41 Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol 2012 0.78
42 Inhibition of p53 sensitizes MCF-7 cells to ceramide treatment. Int J Oncol 2010 0.78
43 Preserving and promoting our discipline: pharmacology students speak out. Mol Interv 2005 0.75